• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.
【24h】

Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.

机译：B-CLL和其他血液系统恶性肿瘤中抗CD200免疫疗法的原理：阻断免疫抑制的新概念。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immune evasion in cancer is increasingly recognized as a contributing factor in the failure of a natural host antitumor immune response as well as in the failure of cancer vaccine trials. Immune evasion may be the result of a number of factors, including expansion of regulatory T cells, production of immunosuppressive cytokines, downregulation of HLA class I and tumor-associated antigens and upregulation of immunosuppressive molecules on the surface of tumor cells. CD200, a cell surface ligand that plays a role in regulating the immune system, has been shown to be upregulated on the surface of some hematologic and solid tumor malignancies. This review characterizes the role of CD200 in immune suppression, and describes strategies to target this molecule in the oncology setting, thus directly modulating immune regulation and potentially altering tolerance to tumor antigens.
机译：越来越多的人认为，癌症的免疫逃逸是导致天然宿主抗肿瘤免疫反应失败以及癌症疫苗试验失败的因素。免疫逃逸可能是多种因素导致的，包括调节性T细胞的扩增，免疫抑制性细胞因子的产生，HLA I类和肿瘤相关抗原的下调以及肿瘤细胞表面上免疫抑制性分子的上调。 CD200是一种在调节免疫系统中发挥作用的细胞表面配体，已显示在某些血液学和实体瘤恶性肿瘤的表面上调。这篇综述描述了CD200在免疫抑制中的作用，并描述了在肿瘤学背景中靶向该分子的策略，从而直接调节免疫调节并可能改变对肿瘤抗原的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号